Recordati Industria Chimica e Farmaceutica SpA
MIL:REC

Watchlist Manager
Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Watchlist
Price: 52.1 EUR 2.86% Market Closed
Market Cap: 10.7B EUR
Have any thoughts about
Recordati Industria Chimica e Farmaceutica SpA?
Write Note

Intrinsic Value

The intrinsic value of one REC stock under the Base Case scenario is 52.94 EUR. Compared to the current market price of 52.1 EUR, Recordati Industria Chimica e Farmaceutica SpA is Undervalued by 2%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

REC Intrinsic Value
52.94 EUR
Undervaluation 2%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Recordati Industria Chimica e Farmaceutica SpA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for REC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about REC?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Recordati Industria Chimica e Farmaceutica SpA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Recordati Industria Chimica e Farmaceutica SpA

Provide an overview of the primary business activities
of Recordati Industria Chimica e Farmaceutica SpA.

What unique competitive advantages
does Recordati Industria Chimica e Farmaceutica SpA hold over its rivals?

What risks and challenges
does Recordati Industria Chimica e Farmaceutica SpA face in the near future?

Summarize the latest earnings call
of Recordati Industria Chimica e Farmaceutica SpA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Recordati Industria Chimica e Farmaceutica SpA.

Provide P/S
for Recordati Industria Chimica e Farmaceutica SpA.

Provide P/E
for Recordati Industria Chimica e Farmaceutica SpA.

Provide P/OCF
for Recordati Industria Chimica e Farmaceutica SpA.

Provide P/FCFE
for Recordati Industria Chimica e Farmaceutica SpA.

Provide P/B
for Recordati Industria Chimica e Farmaceutica SpA.

Provide EV/S
for Recordati Industria Chimica e Farmaceutica SpA.

Provide EV/GP
for Recordati Industria Chimica e Farmaceutica SpA.

Provide EV/EBITDA
for Recordati Industria Chimica e Farmaceutica SpA.

Provide EV/EBIT
for Recordati Industria Chimica e Farmaceutica SpA.

Provide EV/OCF
for Recordati Industria Chimica e Farmaceutica SpA.

Provide EV/FCFF
for Recordati Industria Chimica e Farmaceutica SpA.

Provide EV/IC
for Recordati Industria Chimica e Farmaceutica SpA.

Show me price targets
for Recordati Industria Chimica e Farmaceutica SpA made by professional analysts.

What are the Revenue projections
for Recordati Industria Chimica e Farmaceutica SpA?

How accurate were the past Revenue estimates
for Recordati Industria Chimica e Farmaceutica SpA?

What are the Net Income projections
for Recordati Industria Chimica e Farmaceutica SpA?

How accurate were the past Net Income estimates
for Recordati Industria Chimica e Farmaceutica SpA?

What are the EPS projections
for Recordati Industria Chimica e Farmaceutica SpA?

How accurate were the past EPS estimates
for Recordati Industria Chimica e Farmaceutica SpA?

What are the EBIT projections
for Recordati Industria Chimica e Farmaceutica SpA?

How accurate were the past EBIT estimates
for Recordati Industria Chimica e Farmaceutica SpA?

Compare the revenue forecasts
for Recordati Industria Chimica e Farmaceutica SpA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Recordati Industria Chimica e Farmaceutica SpA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Recordati Industria Chimica e Farmaceutica SpA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Recordati Industria Chimica e Farmaceutica SpA compared to its peers.

Compare the P/E ratios
of Recordati Industria Chimica e Farmaceutica SpA against its peers.

Discuss the investment returns and shareholder value creation
comparing Recordati Industria Chimica e Farmaceutica SpA with its peers.

Analyze the financial leverage
of Recordati Industria Chimica e Farmaceutica SpA compared to its main competitors.

Show all profitability ratios
for Recordati Industria Chimica e Farmaceutica SpA.

Provide ROE
for Recordati Industria Chimica e Farmaceutica SpA.

Provide ROA
for Recordati Industria Chimica e Farmaceutica SpA.

Provide ROIC
for Recordati Industria Chimica e Farmaceutica SpA.

Provide ROCE
for Recordati Industria Chimica e Farmaceutica SpA.

Provide Gross Margin
for Recordati Industria Chimica e Farmaceutica SpA.

Provide Operating Margin
for Recordati Industria Chimica e Farmaceutica SpA.

Provide Net Margin
for Recordati Industria Chimica e Farmaceutica SpA.

Provide FCF Margin
for Recordati Industria Chimica e Farmaceutica SpA.

Show all solvency ratios
for Recordati Industria Chimica e Farmaceutica SpA.

Provide D/E Ratio
for Recordati Industria Chimica e Farmaceutica SpA.

Provide D/A Ratio
for Recordati Industria Chimica e Farmaceutica SpA.

Provide Interest Coverage Ratio
for Recordati Industria Chimica e Farmaceutica SpA.

Provide Altman Z-Score Ratio
for Recordati Industria Chimica e Farmaceutica SpA.

Provide Quick Ratio
for Recordati Industria Chimica e Farmaceutica SpA.

Provide Current Ratio
for Recordati Industria Chimica e Farmaceutica SpA.

Provide Cash Ratio
for Recordati Industria Chimica e Farmaceutica SpA.

What is the historical Revenue growth
over the last 5 years for Recordati Industria Chimica e Farmaceutica SpA?

What is the historical Net Income growth
over the last 5 years for Recordati Industria Chimica e Farmaceutica SpA?

What is the current Free Cash Flow
of Recordati Industria Chimica e Farmaceutica SpA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Recordati Industria Chimica e Farmaceutica SpA.

Business Breakdown

Recordati Industria Chimica e Farmaceutica SpA is a well-established pharmaceutical company based in Italy, renowned for its commitment to innovation and high-quality healthcare solutions. Founded in 1926, Recordati has evolved from a small family business into a global player in the pharmaceutical industry, focusing on the development and marketing of specialty pharmaceuticals, particularly for rare diseases and niche therapeutic areas. With a strategic emphasis on expanding its portfolio through research and development as well as targeted acquisitions, the company showcases a strong pipeline of products designed to address unmet medical needs, thus positioning itself as a crucial player i...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Recordati Industria Chimica e Farmaceutica SpA

Current Assets 1.2B
Cash & Short-Term Investments 200.6m
Receivables 592.2m
Other Current Assets 452.2m
Non-Current Assets 3B
Long-Term Investments 20.8m
PP&E 183m
Intangibles 2.6B
Other Non-Current Assets 104.2m
Current Liabilities 887.2m
Accounts Payable 263.6m
Short-Term Debt 50.3m
Other Current Liabilities 573.3m
Non-Current Liabilities 1.5B
Long-Term Debt 1.4B
Other Non-Current Liabilities 156.5m
Efficiency

Earnings Waterfall
Recordati Industria Chimica e Farmaceutica SpA

Revenue
2.2B EUR
Cost of Revenue
-731.6m EUR
Gross Profit
1.5B EUR
Operating Expenses
-895.9m EUR
Operating Income
596.2m EUR
Other Expenses
-209.1m EUR
Net Income
387m EUR

Free Cash Flow Analysis
Recordati Industria Chimica e Farmaceutica SpA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Recordati reported net revenue of EUR 607 million for Q1 2024, a 10.2% increase year-over-year, bolstered by double-digit growth in both Specialty & Primary Care (SPC) and Rare Disease segments. Despite adverse FX impacts, the company achieved an EBITDA margin of 40.2%. Adjusted net income rose 5.6% to EUR 163.7 million, with free cash flow at EUR 147.1 million. Significant progress was made in R&D, with key drug applications in the pipeline. The company is on track to reach the upper half of its financial targets for 2024 and maintains a positive outlook for 2025.

What is Earnings Call?
Fundamental Scores

REC Profitability Score
Profitability Due Diligence

Recordati Industria Chimica e Farmaceutica SpA's profitability score is 65/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Year Average ROE
Positive Operating Income
65/100
Profitability
Score

Recordati Industria Chimica e Farmaceutica SpA's profitability score is 65/100. The higher the profitability score, the more profitable the company is.

REC Solvency Score
Solvency Due Diligence

Recordati Industria Chimica e Farmaceutica SpA's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
51/100
Solvency
Score

Recordati Industria Chimica e Farmaceutica SpA's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

REC Price Targets Summary
Recordati Industria Chimica e Farmaceutica SpA

Wall Street analysts forecast REC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for REC is 55.95 EUR with a low forecast of 48.48 EUR and a high forecast of 66.15 EUR.

Lowest
Price Target
48.48 EUR
7% Downside
Average
Price Target
55.95 EUR
7% Upside
Highest
Price Target
66.15 EUR
27% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for REC?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for REC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

REC News

Other Videos

Profile

Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA

Country

Italy

Industry

Pharmaceuticals

Market Cap

10.7B EUR

Dividend Yield

3.45%

Description

Recordati SpA engages in the research, development, manufacturing, and marketing of pharmaceuticals. The company is headquartered in Milan, Milano and currently employs 4,303 full-time employees. The company promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The firm is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. The company operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The firm owns and operates through Natural Point srl also in the food supplement sector.

Contact

MILANO
Milan
Via M. Civitali, 1
www.recordati.it

IPO

1984-01-01

Employees

4 303

Officers

CEO & Director
Dr. Robert Koremans M.D.
Group CFO & Executive Director
Mr. Luigi Felice La Corte
Executive Director
Mr. Giorgio De Palma
VP & Head of Investor Relations
Ms. Eugenia Litz
Group Chief Legal Officer
Ms. Bibianne Bon
Group Communications Director
Ms. Laura Conti
Show More
Executive VP of Corporate Development, Licensing & Innovation
Mr. Gabriele Finzi
Group Chief People & Culture Officer
Ms. Alessandra Abate
Show Less

See Also

Discover More
What is the Intrinsic Value of one REC stock?

The intrinsic value of one REC stock under the Base Case scenario is 52.94 EUR.

Is REC stock undervalued or overvalued?

Compared to the current market price of 52.1 EUR, Recordati Industria Chimica e Farmaceutica SpA is Undervalued by 2%.

Back to Top